Baxter International Inc. (BAX) Stake Boosted by Dupont Capital Management Corp
Dupont Capital Management Corp lifted its position in shares of Baxter International Inc. (NYSE:BAX) by 78.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,055 shares of the medical instruments supplier’s stock after purchasing an additional 34,434 shares during the quarter. Dupont Capital Management Corp’s holdings in Baxter International were worth $4,898,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in BAX. BlackRock Inc. boosted its position in shares of Baxter International by 1,941.1% during the first quarter. BlackRock Inc. now owns 46,937,709 shares of the medical instruments supplier’s stock worth $2,434,190,000 after purchasing an additional 44,638,052 shares in the last quarter. Bessemer Group Inc. boosted its position in shares of Baxter International by 42,907.2% during the second quarter. Bessemer Group Inc. now owns 4,652,950 shares of the medical instruments supplier’s stock worth $281,690,000 after purchasing an additional 4,642,131 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Baxter International by 2,859.6% during the first quarter. Renaissance Technologies LLC now owns 1,897,115 shares of the medical instruments supplier’s stock worth $98,384,000 after purchasing an additional 1,833,015 shares in the last quarter. Marshall Wace North America L.P. bought a new position in shares of Baxter International during the first quarter worth $65,780,000. Finally, Vanguard Group Inc. boosted its position in shares of Baxter International by 2.6% during the first quarter. Vanguard Group Inc. now owns 32,765,687 shares of the medical instruments supplier’s stock worth $1,699,228,000 after purchasing an additional 836,708 shares in the last quarter. 83.77% of the stock is currently owned by institutional investors.
In other Baxter International news, Director Carole J. Shapazian sold 4,020 shares of Baxter International stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.61, for a total value of $247,672.20. Following the sale, the director now directly owns 13,868 shares in the company, valued at approximately $854,407.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Giuseppe Accogli sold 12,670 shares of Baxter International stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $60.96, for a total transaction of $772,363.20. Following the completion of the sale, the senior vice president now owns 33,286 shares in the company, valued at $2,029,114.56. The disclosure for this sale can be found here. Insiders sold a total of 35,050 shares of company stock worth $2,158,587 over the last quarter. Company insiders own 0.05% of the company’s stock.
BAX has been the topic of a number of recent analyst reports. BidaskClub cut shares of Baxter International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Cantor Fitzgerald set a $70.00 price target on shares of Baxter International and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $69.00 price target on the stock in a research report on Tuesday, October 10th. BMO Capital Markets reissued a “buy” rating and set a $70.00 price target on shares of Baxter International in a research report on Friday, October 13th. Finally, Morgan Stanley lifted their price target on shares of Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 26th. Six investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Baxter International has a consensus rating of “Buy” and a consensus target price of $67.00.
Shares of Baxter International Inc. (BAX) opened at $64.90 on Friday. Baxter International Inc. has a twelve month low of $43.13 and a twelve month high of $65.70. The company has a current ratio of 3.01, a quick ratio of 2.42 and a debt-to-equity ratio of 0.38. The company has a market cap of $35,359.59, a price-to-earnings ratio of 26.82, a P/E/G ratio of 2.17 and a beta of 0.68.
Baxter International (NYSE:BAX) last issued its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.32%. The firm had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period in the previous year, the business earned $0.56 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. analysts predict that Baxter International Inc. will post 2.43 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Baxter International Inc. (BAX) Stake Boosted by Dupont Capital Management Corp” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/baxter-international-inc-bax-stake-boosted-by-dupont-capital-management-corp/1680721.html.
Baxter International Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.